Presentation is loading. Please wait.

Presentation is loading. Please wait.

Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy 

Published byHorace McBride Modified over 5 years ago

Similar presentations

Presentation on theme: "Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy "— Presentation transcript:

1 Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy  Chao Hui Huang, MD, Michael M. Millenson, MD, Eric J. Sherman, MD, Hossein Borghaei, DO, David M. Mintzer, MD, Roger B. Cohen, MD, Arthur P. Staddon, MD, Judi Seldomridge, RN, BSN, Ocn Joseph Treat, MD, Holly Tuttle, RN, MSN, Karen J. Ruth, MS, Corey J. Langer, MD  Journal of Thoracic Oncology  Volume 3, Issue 9, Pages (September 2008) DOI: /JTO.0b013e c2 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Overall survival and EFS.
Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e c2) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 EFS by time since TDx.
Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e c2) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy "

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
A Hole in the Heart Journal of Thoracic Oncology

A Hole in the Heart Journal of Thoracic Oncology
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
PUBLISH ONLY Journal of Thoracic Oncology

PUBLISH ONLY Journal of Thoracic Oncology
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000–2006  Mark.

Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000–2006  Mark.
Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Hedgehog Signaling Pathway and Lung Cancer

Hedgehog Signaling Pathway and Lung Cancer
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib  Sai-Hong Ignatius Ou, MD, PhD,

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib  Sai-Hong Ignatius Ou, MD, PhD,
Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure  Jessamy A. Boyd, MD, Jessica L. Hubbs,

Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure  Jessamy A. Boyd, MD, Jessica L. Hubbs,

Similar presentations

Ads by Google